Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
the ability to comprehend the data set matrices of mixtures of APIs and excipients and to
forecast drug-excipient interactions, PCA is utilized as a factor analysis tool [70]. Figure 1.3
provides key specified applications of computer simulations in drug delivery.
1.3 Conclusion
Computer simulations have emerged as a crucial tool in drug delivery research, offer-
ing significant advantages in understanding and optimizing the mechanisms of drug
transport and release. The current strategies in this field involve the use of molecular
dynamics, Monte Carlo simulations, and finite element analysis to model various as-
pects of drug delivery systems, including the behavior of nanoparticles, drug-polymer
interactions, and the diffusion processes within biological tissues. These simulations
have enabled researchers to predict the performance of drug delivery systems more
accurately, thereby reducing the need for extensive experimental trials and accelerat-
ing the development process.
The integration of artificial intelligence and machine learning with traditional
simulation methods has further enhanced the predictive power and efficiency of
these models. By leveraging vast datasets and sophisticated algorithms, researchers
can now simulate complex biological environments and predict the outcomes of drug
delivery with greater precision.
Looking to the future, the prospects for computer simulations in drug delivery
are promising. Advances in computational power, coupled with the development of
more refined and comprehensive models, are expected to drive further innovations.
Personalized medicine, where drug delivery systems are tailored to individual patient
profiles, is one area where simulations could have a transformative impact. Addition-
ally, the continuous improvement of simulation techniques will likely lead to more
effective and safer drug delivery systems, ultimately improving patient outcomes and
advancing the field of medicine.
Figure 1.3: Specified applications of computer
simulations in drug delivery.
1 Introduction to computer simulations in drug delivery 13
https://t.me/med1917
References
[1] Wang, W., Ye, Z., Gao, H., & Ouyang, D. Computational pharmaceutics-A new paradigm of drug
delivery. Journal of Controlled Release, 2021 Oct 10, 338, 119–136.
[2] Jovčevska, I., & Muyldermans, S. The therapeutic potential of nanobodies. BioDrugs, 2020 Feb, 34(1),
11–26.
[3] Lee, J. W., Park, J. H., & Robinson, J. R. Bioadhesive‐based dosage forms: The next generation.
Journal of Pharmaceutical Sciences, 2000 Jul 1, 89(7), 850–866.
[4] Lelouche, S. N., Biglione, C., & Horcajada, P. Advances in plasmonic-based MOF composites, their
bio-applications, and perspectives in this field. Expert Opinion on Drug Delivery, 2022 Nov 2, 19(11),
1417–1434.
[5] Park, H., Otte, A., & Park, K. Evolution of drug delivery systems: From 1950 to 2020 and beyond.
Journal of Controlled Release, 2022 Feb 1, 342, 53–65.
[6] Croy, S. R., & Kwon, G. S. Polymeric micelles for drug delivery. Current Pharmaceutical Design, 2006
Dec 1, 12(36), 4669–4684.
[7] Adepu, S., & Ramakrishna, S. Controlled drug delivery systems: Current status and future directions.
Molecules, 2021 Sep 29, 26(19), 5905.
[8] Serov, N., & Vinogradov, V. Artificial intelligence to bring nanomedicine to life. Advanced Drug
Delivery Reviews, 2022 Mar, 10, 114194.
[9] Bannigan, P., Aldeghi, M., Bao, Z., Häse, F., Aspuru-Guzik, A., & Allen, C. Machine learning directed
drug formulation development. Advanced Drug Delivery Reviews, 2021 Aug 1, 175, 113806.
[10] Li, H., Shi, C., Sun, P., Zhang, Y., & Collins, A. L. Attribution of runoff changes in the main tributaries
of the middle yellow river, China, based on the Budyko model with a time-varying parameter.
Catena, 2021 Nov 1, 206, 105557.
[11] Sun, C., Tang, T., & Uludag, H. A molecular dynamics simulation study on the effect of lipid
substitution on polyethylenimine mediated siRNA complexation. Biomaterials, 2013, 34(11),
2822–2833.
[12] Narang, A. S., Desai, D., & Badawy, S. Impact of excipient interactions on solid dosage form stability.
Excipient Applications in Formulation Design and Drug Delivery, 2015, Pharm Res, 2012, 29,
2660–83, 93–137.
[13] Gad, S. C. Oral drug formulation development in pharmaceutical lead selection stage. Oral
Formulation Roadmap from Early Drug Discovery to Development, 2017 Mar, 31, 39–88.
[14] Dai, S., et al. SeDeM expert system for directly compressed tablet formulation: A review and new
perspectives. Powder Technol, 2019, 342, 517–527.
[15] Schuhmacher, A., Gassmann, O., & Hinder, M. Changing R&D models in research-based
pharmaceutical companies. Journal of Translational Medicine, 2016 Dec, 14(1), 1–1.
[16] Hora, P. F., & Stalcup, T. Drug treatment courts in the twenty-first century: The evolution of the
revolution in problem-solving courts. Georgia Law Review, 2007, 42, 717.
[17] Choi, H. S., & Frangioni, J. V. Nanoparticles for biomedical imaging: Fundamentals of clinical
translation. Molecular Imaging, 2010 Nov 1, 9(6), 7290–2010.
[18] Federsel, H. J. Process R&D under the magnifying glass: Organization, business model, challenges,
and scientific context. Bioorganic & Medicinal Chemistry, 2010 Aug 15, 18(16), 5775–5794.
[19] Garg, R. G., & Gupta, G. D. Progress in controlled gastroretentive delivery systems. Tropical Journal
of Pharmaceutical Research, 2008 Sep 11, 7(3), 1055–1066.
[20] Destro, F., & Barolo, M. A review on the modernization of pharmaceutical development and
manufacturing-Trends, perspectives, and the role of mathematical modeling. International Journal
of Pharmaceutics, 2022 Mar, 31, 121715.
[21] Sdf
14 Dilpreet Singh et al.
https://t.me/med1917
[22] He, X. C., Qu, Z. G., & Xu, F. Simulation study of interaction mechanism between peptide and
asymmetric membrane. Molecular Simulation, 2017, 43(1), 34–41.
[23] Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde,
A. Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 2016
Dec, 15, 1–7.
[24] Vivero‐Escoto, J. L., Slowing, I. I., Trewyn, B. G., & Lin, V. S. Mesoporous silica nanoparticles for
intracellular controlled drug delivery. Small, 2010 Sep 20, 6(18), 1952–1967.
[25] Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. Current trends
and challenges in cancer management and therapy using designer nanomaterials. Nano
Convergence, 2019 Dec, 6, 1–30.
[26] Awad, A., Trenfield, S. J., Gaisford, S., & Basit, A. W. 3D printed medicines: A new branch of digital
healthcare. International Journal of Pharmaceutics, 2018 Sep 5, 548(1), 586–596.
[27] Poozesh, S., & Mahdi Jafari, S. Are traditional small-scale screening methods reliable to predict
pharmaceutical spray drying?. Pharmaceutical Development and Technology, 2019 Aug 9, 24(7),
915–925.
[28] Pulley, S., & Collins, A. L. A rapid and inexpensive colour-based sediment tracing method
incorporating hydrogen peroxide sample treatment as an alternative to quantitative source
fingerprinting for catchment management. Journal of Environmental Management, 2022 Jun 1, 311,
114780.
[29] Bailey, J. E. Mathematical modeling and analysis in biochemical engineering: Past accomplishments
and future opportunities. Biotechnology Progress, 1998, 14(1), 8–20.
[30] Bishop, B. W., Hank, C., & Webster, J. IJDC| research paper. International Journal of Digital Curation,
2022, 16(1), 10.
[31] MacKerell, A. D., et al. All-atom empirical potential for molecular modeling and dynamics studies of
proteins. The Journal of Physical Chemistry B, 1998, 102(18), 3586–3616.
[32] Wang, N., Zhang, Y., Wang, W., Ye, Z., Chen, H., Hu, G., & Ouyang, D. How can machine learning and
multiscale modeling benefit ocular drug development?. Advanced Drug Delivery Reviews, 2023 Mar,
10, 114772.
[33] Silva-Júnior, E. F., Aquino, T. M., & Araújo-Júnior, J. X. Quantum mechanical (QM) calculations applied
to ADMET drug prediction: A review. Current Drug Metabolism, 2017, 18(6), 511–526.
[34] Katiyar, R. S., & Jha, P. K. Molecular simulations in drug delivery: Opportunities and challenges.
Wiley Interdisciplinary Reviews: Computational Molecular Science, 2018 Jul, 8(4), e1358.
[35] Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M. Challenges and opportunities with
modelling and simulation in drug discovery and drug development. Xenobiotica, 2007 Nov 1, 37(10–
11), 1295–1310.
[36] Kusal, S., Patil, S., Choudrie, J., Kotecha, K., Mishra, S., & Abraham, A. AI-based conversational
agents: A scoping review from technologies to future directions. IEEE Access, 2022 Aug 23, 10,
92337–92356.
[37] Roco, M. C. National nanotechnology initiative-past, present, future. In: Handbook on Nanoscience,
Engineering and Technology. 2007, (vol. 2, pp. 3–1).
[38] Ouyang, D., et al. Structure and dynamics of multiple cationic vectors− siRNA complexation by
all-atomic molecular dynamics simulations. The Journal of Physical Chemistry B, 2010, 114(28),
9231–9237.
[39] Zhao, Q., et al. Computer-aided formulation design for a highly soluble lutein–cyclodextrin multiple-
component delivery system. Molecular Pharmaceutics, 2018, 15(4), 1664–1673.
[40] Marx, U., Andersson, T. B., Bahinski, A., Beilmann, M., Beken, S., Cassee, F. R., Cirit, M., Daneshian,
M., Fitzpatrick, S., Frey, O., & Gaertner, C. Biology-inspired microphysiological system approaches to
solve the prediction dilemma of substance testing. Altex, 2016, 33(3), 272.
1 Introduction to computer simulations in drug delivery 15
https://t.me/med1917
[41] Li, L., Han, H., Wang, J., Wei, C., Wang, Y., Li, M., Zhou, Y., & Yang, J. Model informed drug
development and regulation in China: Challenges and opportunities. CPT: Pharmacometrics &
Systems Pharmacology, 2019 Feb, 8(2), 59.
[42] Edginton, A. N., Theil, F. P., Schmitt, W., & Willmann, S. Whole body physiologically-based
pharmacokinetic models: Their use in clinical drug development. Expert Opinion on Drug
Metabolism & Toxicology, 2008 Sep 1, 4(9), 1143–1152.
[43] Allen, M. P., Frenkel, D., & Talbot, J. Molecular dynamics simulation using hard particles. Computer
Physics Reports, 1989, 9(6), 301–353.
[44] Mura, C., & McAnany, C. E. An introduction to biomolecular simulations and docking. Molecular
Simulation, 2014 Aug 9, 40(10–11), 732–764.
[45] Beveridge, D. L., & Dicapua, F. M. Free energy via molecular simulation: Applications to chemical
and biomolecular systems. Annual Review of Biophysics and Biophysical Chemistry, 1989 Jun, 18(1),
431–492.
[46] Huynh, L., Grant, J., Leroux, J. C., Delmas, P., & Allen, C. Predicting the solubility of the anti-cancer
agent docetaxel in small molecule excipients using computational methods. Pharmaceutical
Research, 2008 Jan 18, 25(1), 147–157.
[47] Kavassalis, T. A., & Noolandi, J. A new theory of entanglements and dynamics in dense polymer
systems. Macromolecules, 1988 Sep, 21(9), 2869–2879.
[48] Walsh, M. R., Koh, C. A., Sloan, E. D., Sum, A. K., & Wu, D. T. Microsecond simulations of spontaneous
methane hydrate nucleation and growth. Science, 2009, 326(5956), 1095–1098.
[49] Kukhta, N. A., & Luscombe, C. K. Gaining control over conjugated polymer morphology to improve
the performance of organic electronics. Chemical Communications, 2022, 58(50), 6982–6997.
[50] Miteva, M. A., (ed). In-Silico Lead Discovery. 2011, (pp. 142–147). 978(1), Bentham Science Publishers.
[51] Loeffler, H. H., Bosisio, S., Duarte Ramos Matos, G., Suh, D., Roux, B., Mobley, D. L., & Michel,
J. Reproducibility of free energy calculations across different molecular simulation software
packages. Journal of Chemical Theory and Computation, 2018 Oct 5, 14(11), 5567–5582.
[52] Gast, T. F., Schroeder, C., Stomakhin, A., Jiang, C., & Teran, J. M. Optimization integrator for large
time steps. IEEE Transactions on Visualization and Computer Graphics, 2015 Jul 22, 21(10), 1103–1115.
[53] Adcock, S. A., & McCammon, J. A. Molecular dynamics: Survey of methods for simulating the activity
of proteins. Chemical Reviews, 2006 May 10, 106(5), 1589– 1615.
[54] Comer, J., Gumbart, J. C., Hénin, J., Lelièvre, T., Pohorille, A., & Chipot, C. The adaptive biasing force
method: Everything you always wanted to know but were afraid to ask. The Journal of Physical
Chemistry B, 2015 Jan 22, 119(3), 1129– 1151.
[55] Bird, A. 1 1. Epigenetics: DNA methylation and far beyond. Genetics, 2007, 41, 213–236.
[56] Demontis, P., & Suffritti, G. B. A comment on the flexibility of framework in molecular dynamics
simulations of zeolites. Microporous and Mesoporous Materials, 2009 Oct 1, 125(1 –2), 160–168.
[57] Troisi, A., Nitzan, A., & Ratner, M. A. A rate constant expression for charge transfer through
fluctuating bridges. The Journal of Chemical Physics, 2003 Sep 22, 119(12), 5782–5788.
[58] Yu, L. X., Crison, J. R., & Amidon, G. L. Compartmental transit and dispersion model analysis of small
intestinal transit flow in humans. International Journal of Pharmaceutics, 1996, 140(1), 111–118.
[59] Grobelna, I. Formal verification of embedded logic controller specification with computer deduction
in temporal logic. Przeglad Elektrotechniczny, 2011 Jan 1, 87(12a), 47–50.
[60] Beg, S., Swain, S., Rahman, M., Hasnain, M. S., & Imam, S. S. Application of design of experiments
(DoE) in pharmaceutical product and process optimization. InPharmaceutical Quality by Design,
2019 Jan, 1, 43–64.
[61] De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. Role of molecular dynamics and related methods
in drug discovery. Journal of Medicinal Chemistry, 2016 May 12, 59(9), 4035–4061.
[62] Sharifian Gh, M. Recent experimental developments in studying passive membrane transport of
drug molecules. Molecular Pharmaceutics, 2021 Apr 29, 18(6), 2122– 2141.
16 Dilpreet Singh et al.
https://t.me/med1917
[63] Favia, A. D. Theoretical and computational approaches to ligand-based drug discovery. Frontiers in
Bioscience-Landmark, 2011 Jan 1, 16(4), 1276–1290.
[64] Simões, M. F., Pinto, R. M., & Simões, S. Hot-melt extrusion in the pharmaceutical industry: Toward
filing a new drug application. Drug Discovery Today, 2019 Sep 1, 24(9), 1749–1768.
[65] Perez-Ramírez, B., Guziewicz, N., Simler, R., & Sreedhara, A. Approaches for early developability
assessment of proteins to guide quality by design of liquid formulations. Quality by Design for
Biopharmaceutical Drug Product Development, 2015, 4, 87 – 114.
[66] Walters, W. P., & Namchuk, M. Designing screens: How to make your hits a hit. Nature Reviews
Drug Discovery, 2003 Apr 1, 2(4), 259– 266.
[67] García-Mota, M., Bridier, B., Pérez-Ramírez, J., & López, N. Interplay between carbon monoxide,
hydrides, and, carbides in selective alkyne hydrogenation on palladium. Journal of Catalysis, 2010
Jul 28, 273(2), 92–102.
[68] Patel, P., Ahir, K., Patel, V., Manani, L., & Patel, C. Drug-Excipient compatibility studies: First step for
dosage form development. The Pharma Innovation, 2015 Jul 1, 4(5, Part A), 14.
[69] Wentzell, P. D., Giglio, C., & Kompany-Zareh, M. Beyond principal components: A critical comparison
of factor analysis methods for subspace modelling in chemistry. Analytical Methods, 2021, 13(37),
4188–4219.
[70] Hopke, P. K. Factor and correlation analysis of multivariate environmental data. Methods of
Environmental Data Analysis, 1992, 6, 139–180.
[71] Luzar, A., & Chandler, D. (1993). Structure and hydrogen bond dynamics of water–dimethyl sulfoxide
mixtures by computer simulations. The Journal of chemical physics, 98(10), 8160–8173.
[72] Cho, K., & Joannopoulos, J. D. (1992). Ergodicity and dynamical properties of constant-temperature
molecular dynamics. Physical Review A, 45(10), 7089.
[73] Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development settings.
Advanced drug delivery reviews, 64, 4–17.
1 Introduction to computer simulations in drug delivery 17
https://t.me/med1917
https://t.me/med1917
Ram Babu Sharma, Sakshi Tomar, Swati Kaushal, and Amardeep Kaur
2 The role of multiscale approaches
for the rational design of nanoparticulate
drug delivery system: recent advances
Abstract: A novel technique for the creation of all sorts of dosage forms, particularly
nanoparticulate drug delivery systems, is multiscale methods for rational design of
nanoparticle drug delivery systems. Given the repeated claims of the capabilities of
rational creation of all nanoparticulate drug delivery systems, it is now also known as
multiscale computational modeling for drug development systems. Prior to beginning
the experimental work and the potential for generating a dosage form, these compu-
tational multiscale methodologies provide a tangible degree of insight regarding
drug–excipient, excipient–excipient, and drug–patient interactions. It is best to ex-
clude punctuation because research experts are currently using various software for
earlier dosage form creation possibilities. In silico techniques, which are trusted sour-
ces for drug delivery systems, are now being utilized to forecast information about
nanotechnology systems for targeted delivery systems. This chapter’s goal is to iden-
tify the key topics that are crucial for the development and design of drug delivery
systems. To develop nanoparticulate drug delivery systems, many statistical approach
tools are employed, and computational methods have also been made available.
There will be consideration given to future directions and the extension of this para-
digm to new nanotechnology delivery systems.
Keywords: Nanoparticulate, rational design, computational methods, multiscale meth-
odology, nanotechnology
2.1 Introduction to nanoparticulate drug
delivery systems
In the realm of pharmaceutical sciences, nanoparticulate drug delivery systems have
emerged as a viable strategy, revolutionizing the administration of treatments. These
systems, which have several benefits over traditional drug delivery methods, use
nanoparticles as carriers to encapsulate and transport medications to particular tar-
get areas in the body [1].
Ram Babu Sharma, Sakshi Tomar, Swati Kaushal, Amardeep Kaur, Himalayan Institute of
Pharmacy, Kala Amb, Hamidpur 173030, Himachal Pradesh, India
https://doi.org/10.1515/9783111208671-002
https://t.me/med1917
Submicron-sized nanoparticles have special physicochemical characteristics that
can be carefully controlled to enhance drug delivery. They may be made from a vari-
ety of substances, including polymers, lipids, metals, and inorganic compounds, each
with unique properties appropriate for varied uses. Due to their tiny size, nanopar-
ticles can passively accumulate in disease areas and tumor tissues with weakened vas-
culature due to the increased enhanced permeability and retention (EPR) effect [2].
The selection of drugs, particle size and shape, surface modification, and targeting
techniques are only a few of the variables that must be carefully taken into account
when designing rational nanoparticulate drug delivery systems. Drug loading capac-
ity, release kinetics, and stability may all be improved with the right materials and
particle characteristics, which will increase therapeutic efficacy and lessen adverse
effects.
The process of rational design greatly benefits from the use of molecular model-
ing tools like computational chemistry and molecular dynamics simulations. These
methods enable the evaluation of stability and release patterns, the optimization of
drug loading, and the prediction of drug–particle interactions. The creation of more
effective drug delivery systems is made possible by molecular modeling, which simu-
lates the behavior of nanoparticles at the molecular level [3].
Researchers may precisely manipulate particle features using nanoengineering
techniques, allowing them to modify the properties of nanoparticles to meet particu-
lar needs. The creation of nanoparticles with specific size, shape, and surface features
is made po ssible by bottom-up processes including nanoprecipitation and emulsion-
based procedures. To shrink bigger particles to nanoscale sizes, top-down techniques
can be used, such as high-pressure homogenization and ball milling [4].
Analyzing the functioning and therapeutic efficiency of nanoparticulate drug de-
livery devices requires both in vitro and in vivo investigations. Insights into drug re-
lease kinetics, cellular uptake, pharmacokinetics, and biodistribution characteristics
are provided by these investigations. The effectiveness of nanoparticulate drug deliv-
ery systems may be improved by researchers by combining data from several scales,
such as molecular modeling, nanoengineering, and preclinical trials [5].
2.2 Rational design principles for nanoparticulate
drug delivery systems
A methodical approach is used in the rational design of nanoparticulate drug delivery
systems to maximize their functionality and therapeutic efficacy. In order to success-
fully distribute medications to the body’s target areas, the design process is guided by
a number of fundamental concepts and factors. The importance of these logical design
concepts in the creation of nanoparticulate drug delivery devices will be examined in
this chapter.
20 Ram Babu Sharma et al.
https://t.me/med1917
2.2.1 Drug selection
A critical component of rational design is choosing the best medicine. Considerations
must be made for elements including medication solubility, stability, and therapeutic
index. To enable effective loading, controlled release, and improved drug stability
during storage and circulation, the physicochemical features of the medication and
the nanoparticle carrier should match [6].
2.2.2 Particle size and shape
The behavior of nanoparticles inside the body is significantly influenced by their size
and form. Biodistribution, cellular uptake, and clearance kinetics are all impacted by
particle size. The accumulation of nanoparticles in target tissues can be enhanced
while minimizing off-target distribution and lowering the likelihood of reticuloendo-
thelial system absorption and clearance by carefully choosing particle size [7].
2.2.3 Surface modification
The interactions of nanoparticles and biological systems may be precisely controlled
via surface modification. Researchers can increase stability, extend circulation dura-
tion, improve biocompatibility, and simplify precise targeting to targeted areas by
adding polymers, surfactants, or targeting ligands to the surface. Additionally, surface
modification enables the attachment of useful molecules, such as imaging molecules
or stimuli-responsive groups, to enable triggered drug release or real-time observa-
tion of nanoparticle behavior [8].
2.2.4 Targeting strategies
A crucial component of rational design is targeted delivery, which enables accurate
medication localization and reduces systemic toxicity. Passive targeting depends on the
EPR effect and takes advantage of the leaky vasculature and inadequate lymphatic
drainage of tumor tissues. In order to precisely recognize and bind to receptors or anti-
gens that are overexpressed on target cells or tissues, active targeting entails conjugat-
ing ligands, antibodies, or peptides to nanoparticle surfaces. The therapeutic effects of
nanoparticulate drug delivery systems can be further improved by combination techni-
ques that incorporate both passive and active targeting [9].
2 The role of multiscale approaches for the rational design 21
https://t.me/med1917
2.2.5 Stability and release kinetics
The integrity and drug-loading capacity o f nanoparticulate drug delivery devices
must be maintained during storage and circulation. The concepts of rational design
take into account methods for preventing particle aggregation, preserving drug stabil-
ity, and managing drug release kinetics. To achieve this, appropriate materials must
be chosen, formulation parameters must be optimized, and stimuli-responsive compo-
nents must be included. These components allow for triggered release in response to
particular environmental signals, such as pH, temperature, or enzyme activity.
The framework provided by these rational design principles may be used to cre-
ate effective and precise nanoparticulate drug delivery devices. Researchers can opti-
mize medication distribution, improve therapeutic efficacy, reduce off-target effects,
and systemic toxicity by carefully taking these concepts into account [10].
2.3 Multiscale approaches in nanoparticulate design
Multiscale methods are essential for the rational design of nanoparticulate drug deliv-
ery systems because they allow for a thorough knowledge of their behavior and per-
formance optimization. The complicated interactions between nanoparticles and
biological systems can be better understood by combining data from several scales,
such as molecular modelling, nanoengineering, and in vitro/in vivo experiments. The
relevance of multiscale techniques and their effect on nanoparticulate design will be
examined in thi s discussion [11]. The multiple-scale approaches in various fields is
shown diagrammatically in Figure 2.1
Figure 2.1: Representation of multiple-scale approaches.
22 Ram Babu Sharma et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана